Biospecifics Technologies (BSTC) Reports Q2 EPS of $0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BioSpecifics Technologies Corp. Reports Second Quarter 2015 Financial Results
August 10, 2015 4:01 PM EDTLYNBROOK, N.Y., Aug. 10, 2015 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in Europe, today announced its financial results for the second quarter ended June 30, 2015 and provided a corporate update.
"We continue to focus on expanding the addressable opportunities for XIAFLEX® both commercially and clinically. We were very pleased to announce last month that Asahi Kasei... More
